Stocktoria
HARROW, INC. HROW
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-02-08
HARROW, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $272.3M | $199.6M | $130.2M | $88.6M | $72.5M |
| Gross profit | $204.4M | $150.4M | $90.6M | $63.2M | $54.3M |
| R&D expense | $20.9M | $12.2M | $6.7M | $3.0M | $11.1M |
| SG&A expense | $152.9M | $129.1M | $83.1M | $58.2M | $41.3M |
| Operating income | $30.5M | $8.8M | $431,000 | $1.9M | $1.6M |
| Interest expense | — | — | $21.3M | $7.2M | $5.4M |
| Income tax | $3.8M | $161,000 | $701,000 | $75,000 | $133,000 |
| Net income | -$5.1M | -$17.5M | -$24.4M | -$14.1M | -$18.0M |
| EPS (diluted) | $-0.14 | $-0.49 | $-0.75 | $-0.51 | — |
| Operating cash flow | $43.9M | -$22.2M | $3.8M | $1.7M | $5.1M |
| Free cash flow | $43.0M | -$23.8M | $2.4M | -$892,000 | $3.3M |
| Cash & equivalents | $72.9M | $47.2M | $74.1M | $96.3M | $42.2M |
| Inventory | $13.5M | $10.7M | $10.9M | $6.5M | $4.2M |
| Total assets | $399.5M | $389.0M | $312.2M | $157.4M | $98.3M |
| Total liabilities | $347.4M | $319.7M | $241.8M | $130.1M | $87.4M |
| Shareholders' equity | $52.4M | $69.7M | $70.8M | $27.6M | $11.3M |
Source: SEC EDGAR filings · CIK 0001360214 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.